Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
12 Junho 2023 - 9:31AM
Business Wire
- A scientific-data oral presentation, two
posters and a symposium presentation will highlight the clinical
and research advantages of the company’s Afirma molecular test and
capabilities -
Veracyte, Inc. (Nasdaq: VCYT) today announced that three
abstracts highlighting new data on the company’s Afirma test and
capabilities will be presented at ENDO 2023, the annual meeting of
The Endocrine Society, which is taking place June 15-18 in Chicago,
Ill. Additionally, Veracyte’s medical director of Endocrinology,
Joshua Klopper, M.D., will participate in a symposium panel
discussion on the advantages of various molecular testing
approaches to help personalize and improve care for people with
potentially cancerous thyroid nodules.
“The new data we will share at ENDO 2023 demonstrate Veracyte’s
ongoing commitment to advancing the science around thyroid nodule
management and cancer,” said Dr. Klopper. “They show how we are
helping physicians further personalize treatment for their patients
with thyroid nodules, while also helping researchers identify
additional molecular characteristics of these nodules that could
potentially provide clinically actionable prognostic
information.”
The following abstracts will be presented at the ENDO 2023
meeting, with all presentations taking place at McCormick
Place:
Title: Cytologic and Molecular Assessment of Isthmus
Thyroid Nodules Presenter: Sina Jasim, M.D., M.P.H.,
Washington University in St. Louis Abstract: P85
Session: Poster Session – Late Breaking Poster Abstracts
Date/Time: June 15, 12:30 – 1:30 p.m. CT Location:
ENDO Expo Hall
Title: Analytical Validation of a Telomerase Reverse
Transcriptase (TERT) Promoter Mutation Assay Presenter:
Priyanka Iyer, M.D., M.D. Anderson Cancer Center Abstract:
P87 Session: Poster Session - Late Breaking Poster Abstracts
Date/Time: June 17, 1:00 – 2:00 p.m. CT Location:
ENDO Expo Hall
Title: mRNA Expression Based Tumor Behavior Prediction
Models in Thyroid Nodules Presenter: Allan Golding, M.D.,
Memorial Healthcare System Abstract: OR32-03 Session:
Oral Presentation - Predicting Thyroid Malignancy: What Tools Do We
Have? Date/Time: June 18, 8:30 – 8:45 a.m. CT
Location: Room W-176
In addition to the new data that will be shared during these
presentations, Dr. Klopper will provide his perspective on the role
and advantages of Afirma molecular testing during the
above-mentioned symposium taking place June 17 from 8:40-9:30 a.m.
CT in McCormick Place Room W-181.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that Veracyte data show how
Veracyte helps physicians further personalize treatment for
patients with thyroid nodules and also helps researchers identify
additional molecular characteristics of thyroid nodules that could
potentially provide clinically actionable prognostic information.
Additional factors that may impact these forward-looking statements
can be found under the caption “Risk Factors” in our Annual Report
on Form 10-K filed on February 22, 2023, and our Quarterly Report
on Form 10-Q filed for the three months ended December 31, 2022.
Copies of these documents, when available, may be found in the
Investors section of our website at https://investor.veracyte.com.
These forward-looking statements speak only as of the date hereof
and, except as required by law, we specifically disclaim any
obligation to update these forward-looking statements or reasons
why actual results might differ, whether as a result of new
information, future events or otherwise.
Veracyte, the Veracyte logo and Afirma are registered trademarks
of Veracyte, Inc. and its subsidiaries in the U.S. and selected
countries.
Veracyte delivers the Afirma Genomic Sequencing Classifier and
TERT DNA analysis from its CLIA laboratory. These tests are not
CE-IVD marked and have not been cleared or approved by the FDA;
their performance characteristics were determined by Veracyte and
they might be considered for Research Use Only in some markets.
Please contact Veracyte for confirmation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612366232/en/
Investors: Shayla Gorman Director, Investor Relations
investors@veracyte.com 619-393-1545
Media: Tracy Morris Vice President, Global Corporate
Communications tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024